查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1928660

第三方醫療保健市場按服務類型、交付管道、所有權類型、支付類型和最終用戶類型分類的全球預測（2026-2032 年）

Third-party Medical Institutions Market by Service Type, Delivery Channel, Ownership Model, Payment Model, End User Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，第三方醫療保健提供者市場價值將達到 74.3 億美元，到 2026 年將成長至 80.7 億美元，複合年成長率為 8.91%，到 2032 年將達到 135.2 億美元。

關鍵市場統計數據
基準年 2025 74.3億美元
預計年份：2026年 80.7億美元
預測年份 2032 135.2億美元
複合年成長率 (%) 8.91%

權威指南闡述了第三方服務提供者在現代醫療保健服務中的策略重要性、範圍和相關人員相關性。

現代醫療保健環境瞬息萬變，第三方服務提供者在拓展醫療服務能力、提供專科護理服務以及支援整合式醫療路徑方面發揮日益重要的作用。本導言闡明了報告的定位，並介紹了研究的策略目標，旨在為管理或依賴外包臨床服務、診斷平台、居家醫療服務和替代支付方式的相關人員提供參考。導言強調了高品質、可操作的資訊對於支援籌資策略、夥伴關係評估以及在各種醫療服務提供者和支付方環境中的營運設計的重要性。

對重塑第三方醫療服務提供者的結構和技術力量進行全面分析，並探討這些力量將如何重新定義臨床和經營模式。

醫療保健領域正經歷著一場由技術應用、政策演變和患者期望變化所驅動的變革。這些變化正在重塑第三方醫療機構的營運模式。其中一個關鍵促進因素是虛擬醫療和遠端醫療的興起，這不僅拓展了遠端醫療和居家醫療服務的範圍，也迫使診斷和門診醫療服務提供者將數位化工作流程和遠端監測融入其核心服務中。同時，診斷影像技術的進步正在提升非侵入性檢查的臨床效用，重塑門診和住院領域的轉診模式和投資重點。

對近期美國關稅對外包臨床服務提供者的採購、供應商策略和資本規劃的影響進行基於證據的評估

美國近期推出的關稅政策對依賴跨境醫療設備、耗材和技術服務的醫療機構的供應鏈、採購經濟效益和策略採購決策產生了累積影響。其影響遠不止價格調整；關稅還波及採購計畫、供應商關係及資本投資方案。為此，醫療機構及其供應商合作夥伴正在加快供應鏈風險評估，並將採購重點重新分配給擁有多元化製造地的供應商。

多維度細分分析表明，服務類型、交付管道、所有權結構、支付模式和最終用戶如何共同決定策略重點和營運選擇。

細分市場層面的趨勢揭示了不同服務類型、交付管道、所有權模式、支付機制和最終用戶群所面臨的獨特策略機會和營運挑戰。在服務類型方面，隨著臨床通訊協定的調整和醫療機構對手術全期物流的最佳化，門診手術服務正朝著更高吞吐量和當日手術路徑發展。診斷影像服務正圍繞影像模式的專業化進行重組。 CT、PET 和 X 光等電離輻射成像顯像模式繼續支持急性診斷和介入指導，而 MRI 和超音波等非電離輻射顯像模式則在慢性病管理和照護現場決策支援方面發揮越來越重要的作用。透析服務正在努力平衡中心透析需求與居家透析模式和技術輔助監測的成長。居家醫療服務正在整合遠距監測、專業護理支援和遠端醫療分診，以將護理延伸至患者家中。實驗室服務正在優先考慮自動化、快速出結果和電子健康記錄整合，以支援臨床決策。遠端醫療服務正從一次性虛擬諮詢發展為連結專科醫生和基層醫療機構的連續性照護模式。

區域分析：探討美洲、歐洲、中東和非洲以及亞太地區之間的差異如何影響策略重點、監管方式和服務提供模式。

區域趨勢導致法規環境、患者期望和醫療服務系統有顯著差異，進而影響第三方醫療服務提供者之間的競爭與合作。美洲的市場結構特點是擁有先進的臨床基礎設施和多元化的支付模式，同時私部門的參與度不斷提高，並專注於以患者為中心的門診服務。投資往往集中於擴大門診手術和先進影像技術，而居家照護也隨著人口結構的變化而發展。

競爭行為分析：利用聯盟、能力投資和選擇性整合來擴大規模並提供綜合臨床服務

第三方醫療保健領域的活動以策略聯盟、針對性投資以拓展能力以及選擇性整合為特徵，旨在擴大規模並提升專業水平。領先機構優先考慮跨領域合作，將臨床能力與數位平台結合，以實現更整合的患者診療路徑和一致的品質標準。併購活動的目標是互補資產，例如診斷連鎖機構、實驗室網路和居家照護平台，以建立多站點佈局並簡化轉診流程。

為領導者提供切實可行的優先建議，以增強韌性、加速整合，並使商業模式與不斷變化的支付方和患者期望保持一致。

產業領導者必須採取策略行動，在短期營運穩定與長期能力建設和合作夥伴生態系統發展之間取得平衡。首先，他們應優先增強採購韌性，具體措施包括：透過供應商關係多元化和評估資本設備的總擁有成本，降低政策和供應鏈衝擊帶來的風險。同時，也應有針對性地投資於模組化、可升級技術，以延長設備使用壽命，並在無需大規模資本重新配置的情況下實現產能的逐步擴張。

我們將透明地解釋用於收集專家見解、檢驗假設以及進行細分和地理分析的定性和三角調查方法。

本報告的調查方法結合了定性專家訪談、與關鍵相關人員的面對面交流，以及對已發表的政策文件和臨床文獻的系統性綜合分析。主要資料收集工作包括與來自門診、診斷和居家醫療機構的營運負責人、採購專業人員和支付方代表進行對話，以深入了解實際營運挑戰、合約偏好和技術採納模式。專家見解與監管文件、臨床指南和供應商產品資料的二次分析相結合，以檢驗功能並為策略性舉措提供背景資訊。

一份簡潔明了、結論性的綜合報告，強調了臨床能力、採購和支付方參與的策略協同如何確保營運韌性和競爭優勢。

總之，第三方醫療服務提供者在現代醫療保健領域佔據著戰略前沿，提供必要的醫療能力、專科服務和靈活的診療路徑，以滿足不斷變化的人口結構和患者日益成長的期望。技術、監管和支付方獎勵機制的結構性轉變正促使醫療服務提供者重組服務提供模式、最佳化採購流程並加強與整個醫療服務鏈的夥伴關係。積極投資於互通性、供應鏈韌性和結果衡量的機構將更有能力應對市場波動，並與支付方和醫療系統簽訂永續的合約。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按服務類型分類的第三方醫療保健市場

  • 門診手術服務
  • 診斷影像服務
    • 電離輻射成像
      • CT
      • PET
      • X光
    • 非電離輻射成像
      • MRI
      • 超音波
  • 透析服務
  • 居家醫療服務
  • 檢查服務
  • 遠端醫療服務

第9章：按服務類型分類的第三方醫療機構市場

  • 居家醫療
  • 住院治療
  • 門診治療

第10章：按所有權類型分類的第三方醫療保健市場

  • 私營營利企業
  • 私營非營利組織
  • 民眾

11. 按支付模式分類的第三方醫療保健市場

  • 綜合支付
  • 固定利率支付
  • 計量型

第12章：以最終用戶類型分類的第三方醫療保健市場

  • 診所
  • 醫院
  • 病人

第13章：各地區的第三方醫療保健市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 第三方醫療保健市場（依集團分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國第三方醫療保健市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國第三方醫療保健市場

第17章：中國第三方醫療機構市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ACM Global Laboratories
  • ARUP Laboratories, Inc.
  • BioReference Laboratories, Inc.
  • Cerba Research SAS
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific SE
  • ICON Public Limited Company
  • Laboratory Corporation of America Holdings
  • Myriad Genetics, Inc.
  • NeoGenomics Laboratories, Inc.
  • PPD, Inc.
  • Quest Diagnostics Incorporated
  • Sonic Healthcare Limited
  • Synlab International GmbH
Product Code: MRR-92740D85F099

The Third-party Medical Institutions Market was valued at USD 7.43 billion in 2025 and is projected to grow to USD 8.07 billion in 2026, with a CAGR of 8.91%, reaching USD 13.52 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 7.43 billion
Estimated Year [2026] USD 8.07 billion
Forecast Year [2032] USD 13.52 billion
CAGR (%) 8.91%

An authoritative orientation that frames the strategic importance, scope, and stakeholder relevance of third-party medical institutions in modern healthcare delivery

The contemporary healthcare environment is marked by accelerating change, where third-party medical institutions play an increasingly pivotal role in extending capacity, enabling specialty services, and supporting integrated care pathways. This introduction frames the strategic purpose of the research by clarifying the report's orientation toward stakeholders who manage or rely on outsourced clinical services, diagnostic platforms, home-based care delivery, and alternative payment arrangements. It articulates the need for high-quality, actionable intelligence that supports procurement strategy, partnership evaluation, and operational design across a spectrum of provider and payer settings.

Contextualizing the study, the report emphasizes the convergence of technological innovation, regulatory shifts, and shifting patient expectations that are reshaping how care is delivered and purchased. Analysts and executives will find that the report synthesizes qualitative insights from provider leaders, payers, and supply chain specialists, and interprets policy developments relevant to third-party institutional models. It also identifies the structural levers that institutions can use to enhance resilience, improve patient access, and optimize cost-efficiency without sacrificing clinical quality.

Throughout this introduction, the intent is to orient readers to the report's scope and to clarify how subsequent sections will unpack market dynamics, segmentation-based insights, regional variations, corporate activity, and practical recommendations. By establishing a clear narrative thread, the introduction prepares readers to move seamlessly from high-level trends into deeper analysis and operationally focused guidance.

A comprehensive analysis of the structural and technological forces reshaping third-party care providers and how these forces redefine clinical and business models

The healthcare landscape is undergoing transformative shifts driven by technological adoption, policy evolution, and changing patient expectations, and these shifts are altering the operating model for third-party medical institutions. One major vector of change is the normalization of virtual and remote modalities, which is expanding the remit of telemedicine and home healthcare services while compelling diagnostic and ambulatory providers to integrate digital workflows and remote monitoring into core service delivery. Concurrently, diagnostic imaging advances are increasing the clinical utility of non-invasive modalities, which is reshaping referral patterns and investment priorities across outpatient and inpatient settings.

Regulatory and reimbursement changes are also redefining incentives. New payment arrangements and value-based contracting models are motivating third-party providers to demonstrate care coordination capabilities, measurable outcomes, and cost management. As a result, providers are forming tighter partnerships with hospitals, clinics, and payer networks to manage care across settings. Supply chain resilience and procurement agility have moved to the top of the agenda; providers are diversifying sourcing strategies and adopting modular equipment procurement to reduce operational risk.

Workforce dynamics present another critical axis of transformation. Shortages of specialized staff and rising labor costs are accelerating the adoption of task-shifting models, remote interpretation services, and automation in laboratory and imaging workflows. These operational adaptations are enabling institutions to maintain service volumes while addressing quality and safety standards. Lastly, patient expectations around convenience, transparency, and outcome visibility are prompting providers to redesign the patient journey, with greater emphasis on outpatient access, rapid diagnostics, and integrated digital touchpoints that support continuity of care across the provider network.

An evidence-based evaluation of how recent U.S. tariff measures have influenced procurement, supplier strategies, and capital planning across outsourced clinical service providers

Recent tariff policies enacted by the United States have had a cumulative impact across supply chains, procurement economics, and strategic sourcing decisions for institutions that rely on cross-border medical equipment, consumables, and technical services. The aggregate effect is not limited to price adjustments; tariffs have propagated through procurement timelines, supplier relationships, and capital investment planning. In response, institutions and their vendor partners have accelerated supply chain risk assessments and are reallocating procurement priorities toward suppliers with diversified manufacturing footprints.

These tariff effects have influenced capital equipment acquisition strategies, particularly for diagnostic imaging and laboratory instrumentation where lead times and technical support are critical. Procurement officers are increasingly factoring total cost of ownership and service continuity into vendor selection, and are seeking instruments with modular upgrade paths to avoid frequent capital outlays. At the same time, tariffs have incentivized consideration of nearshoring and regional manufacturing partnerships to reduce exposure to policy volatility and to shorten replenishment cycles.

Policy-driven cost pressures are also reshaping commercial negotiations between third-party providers and payers. Service contracts now more frequently include clauses that address input-cost variability and incorporate shared-risk elements to protect both providers and purchasers. Moreover, these trade measures have prompted companies to reassess global distribution models and to explore localized service networks that preserve clinical availability while managing operating margins. Taken together, tariff-related dynamics are prompting an industry-wide emphasis on procurement agility, supplier diversification, and resilient service models that prioritize continuity of patient care.

A multifaceted segmentation analysis showing how service types, delivery channels, ownership structures, payment models, and end users collectively determine strategic priorities and operational choices

Segment-level dynamics reveal differentiated strategic opportunities and operational challenges across service types, delivery channels, ownership models, payment mechanisms, and end users. Within service type, ambulatory surgery services are evolving toward higher throughput and same-day care pathways as clinical protocols adapt and as facilities optimize perioperative logistics. Diagnostic imaging services are being reconfigured around modality specialization; ionizing imaging modalities such as CT, PET, and X ray continue to support acute diagnostics and interventional guidance, while non-ionizing imaging modalities including MRI and ultrasound are expanding their roles in chronic disease management and point-of-care decision support. Dialysis services are balancing in-center demand with the growth of home-based modalities and technology-enabled monitoring. Home healthcare services are integrating remote monitoring, skilled nursing support, and telehealth triage to extend care into the patient's home. Laboratory services are prioritizing automation, rapid turnaround, and connectivity to electronic health records to support clinical decision-making. Telemedicine services are maturing from episodic virtual visits to longitudinal care models that coordinate across specialists and primary care.

Delivery channels influence how services are accessed and reimbursed. Home care pathways are enabling chronic disease management and post-acute recovery outside institutional walls, whereas inpatient delivery remains the backbone for acute care and complex interventions, and outpatient settings are increasingly the locus for diagnostics and minor procedures that were previously confined to hospitals. Ownership models shape capital allocation and strategic priorities; private for-profit entities often prioritize operational efficiency and growth through scale, private non-profit operators tend to emphasize community outcomes and integrated partnerships with local health systems, and public ownership brings policy-driven mandates and broader population health responsibilities. Payment models exert a strong influence on provider behavior: bundled payments encourage integrated episode-based coordination, capitation incentivizes preventive care and population health management, and fee for service continues to underpin procedural volume economics and per-service reimbursement strategies. End user types drive service design and commercial approaches; clinics focus on workflow efficiency and referral management, hospitals prioritize throughput and inpatient-outpatient integration, and patients demand convenience, transparency, and measurable clinical benefit.

Taken together, these segmentation axes underscore the necessity for providers and partners to adopt differentiated strategies. Some institutions will strengthen modality-specific centers of excellence, others will expand home and outpatient offerings, and many will blend ownership-aligned governance with payment-sensitive contracting to remain competitive. Consequently, segmentation-aware strategy development is essential for aligning capital, talent, and technology investments with patient needs and reimbursement realities.

A regional synthesis highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific variations shape strategic priorities, regulatory approaches, and service delivery models

Regional dynamics introduce significant variability in regulatory environments, patient expectations, and provider ecosystems, which in turn affect how third-party medical institutions compete and collaborate. In the Americas, the market is characterized by a mix of advanced clinical infrastructure and diverse payer models, with strong private sector participation and growing emphasis on patient-centered outpatient care. Investment flows often target capacity expansion for ambulatory surgery and advanced imaging, while home-based services are scaling in response to demographic pressures.

In Europe, the Middle East & Africa, healthcare systems vary widely from centralized public provision to mixed-market models, and this diversity affects provider incentives and partnership structures. Regulatory frameworks in several European markets favor interoperability and outcomes measurement, which encourages integration between third-party providers and national health systems. Across the Middle East and Africa, infrastructure gaps and workforce constraints create opportunities for third-party institutions to deliver scalable diagnostic and laboratory services, often in partnership with international technology providers.

The Asia-Pacific region presents a heterogeneous landscape where rapid urbanization, technological adoption, and a rising middle class are driving demand for convenient, high-quality care. Public and private players are investing in outpatient networks and home care capabilities, and digital health adoption is accelerating service delivery innovation. Across these regions, cross-border collaboration, regional supply chains, and regulatory harmonization initiatives are increasingly important considerations for institutions planning expansion or partnerships. Ultimately, region-specific strategies that account for payer mix, regulatory nuance, and population health priorities will be critical for sustained growth and operational resilience.

An examination of competitive behavior showing how partnerships, capability investments, and selective consolidation are being used to build scale and deliver integrated clinical services

Corporate activity in the third-party medical institution landscape is marked by strategic partnerships, targeted investments in capability expansion, and selective consolidation to gain scale or specialized expertise. Leading organizations are prioritizing cross-sector alliances that combine clinical capacity with digital platforms, thereby enabling more integrated patient pathways and consistent quality standards. Merger and acquisition activity often targets complementary assets such as diagnostic chains, laboratory networks, or home care platforms to create multi-site operational footprints and to streamline referral flows.

Investment priorities center on technology-enabled service delivery, with capital directed toward imaging upgrades that improve diagnostic yield, laboratory automation that reduces turnaround time, and telehealth platforms that support continuity of care. Strategic investors and corporate development teams are also allocating resources to build or acquire expertise in regulatory compliance, outcomes measurement, and payer contracting, recognizing that these capabilities are essential for value-based arrangements. In addition, some companies are experimenting with service bundles and managed care partnerships that align incentives across episodes of care and that extend the provider's role into population health management.

Competitive differentiation increasingly relies on demonstrable clinical outcomes, operational reliability, and the ability to integrate with broader care ecosystems. Firms that combine clinical excellence with predictable service delivery, transparent pricing, and robust data interoperability are positioned to secure long-term contracts with health systems and payers. As a result, corporate strategies are converging on the dual objectives of expanding service breadth while deepening technical and contractual capabilities that support accountable care models.

Practical and prioritized recommendations for how leaders can strengthen resilience, accelerate integration, and align commercial models with evolving payer and patient expectations

Industry leaders must adopt strategic actions that balance near-term operational stability with longer-term investments in capability and partner ecosystems. First, leaders should prioritize strengthening procurement resilience by diversifying supplier relationships and assessing total cost of ownership for capital equipment, thereby reducing exposure to policy and supply-chain shocks. This should be complemented by targeted investments in modular, upgradeable technologies that extend equipment lifecycles and enable incremental capability expansions without major capital redeployments.

Second, organizations should accelerate digital integration across service lines to ensure data flows seamlessly between diagnostic, ambulatory, home care, and telemedicine venues. Interoperability investments will improve care coordination, enable more effective outcomes measurement, and support value-based contracting. Third, payment-model flexibility is essential; providers should develop contracting playbooks for bundled payments and capitation while retaining operational pathways to serve fee-for-service arrangements. This dual capability will allow providers to tailor offerings to payer needs and to negotiate risk-sharing arrangements with confidence.

Fourth, workforce strategies must emphasize both retention and skill mix optimization. Leaders should invest in remote interpretation, task-shifting models, and continuous education programs to mitigate specialist shortages and to enhance productivity. Fifth, regional expansion should be pursued with careful regulatory due diligence and partner selection; local partnerships and joint ventures can accelerate market entry while mitigating compliance and cultural risks. Finally, leaders should embed outcomes-focused performance metrics into commercial negotiations and internal governance to align incentives across clinicians, administrators, and payers. These measures together will help institutions remain responsive to demand shifts and resilient in the face of external disruptions.

A transparent description of the qualitative and triangulated research methods used to gather expert insight, validate assumptions, and structure the segmentation and regional analyses

The research methodology underpinning this report combines qualitative expert interviews, primary stakeholder engagement, and a structured synthesis of publicly available policy and clinical literature. Primary data collection included conversations with operational leaders in ambulatory, diagnostic, and home-based care settings, procurement specialists, and payer representatives to capture real-world perspectives on operational challenges, contracting preferences, and technology adoption patterns. Expert inputs were triangulated with secondary analysis of regulatory filings, clinical guidelines, and vendor product documentation to verify capabilities and to contextualize strategic moves.

Analytical approaches emphasized cross-validation and scenario analysis to test how different regulatory and supply-chain conditions might influence provider responses. Segmentation analysis was conducted by mapping service types, delivery channels, ownership models, payment frameworks, and end-user categories to observed behaviors and strategic choices. Regional assessments drew on policy reviews and stakeholder interviews to identify distinctive drivers and constraints in the Americas, Europe Middle East & Africa, and Asia-Pacific. Care was taken to ensure methodological transparency by documenting data sources, interview protocols, and analytical assumptions in the report appendices.

Limitations of the methodology were acknowledged, including the inherent variability in policy landscapes and the evolving nature of technology adoption. To mitigate these limitations, the methodology incorporated iterative validation with subject-matter experts and sensitivity checks that explored how different operational priorities influence strategic outcomes. The result is a robust qualitative foundation that supports practical recommendations and helps decision-makers interpret how macro trends are likely to play out across different institutional contexts.

A concise concluding synthesis that reinforces how strategic alignment across clinical capabilities, procurement, and payer engagement secures operational resilience and competitive advantage

In conclusion, third-party medical institutions occupy a strategic frontier in contemporary healthcare, providing essential capacity, specialized services, and flexible care pathways that respond to demographic change and evolving patient expectations. Structural shifts in technology, regulation, and payer incentives are prompting providers to reconfigure service delivery, optimize procurement, and strengthen partnerships across the care continuum. Those organizations that proactively invest in interoperability, supply chain resilience, and outcomes measurement will be better positioned to navigate volatility and to secure durable contracts with payers and health systems.

Operationally, the interplay between modality specialization, delivery channel optimization, and payment-model agility will determine competitive positioning. Leaders who align capital investments with segmentation-specific strategies and who pursue regionally tailored expansion plans can balance growth with operational resilience. By embedding performance metrics into governance and by negotiating contracts that reflect input-cost variability, providers can build sustainable models that preserve quality while managing financial risk. The overall imperative is clear: integrate clinical excellence with commercial discipline to deliver care that is accessible, reliable, and demonstrably effective.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Third-party Medical Institutions Market, by Service Type

  • 8.1. Ambulatory Surgery Services
  • 8.2. Diagnostic Imaging Services
    • 8.2.1. Ionizing Imaging
      • 8.2.1.1. CT
      • 8.2.1.2. PET
      • 8.2.1.3. X Ray
    • 8.2.2. Non Ionizing Imaging
      • 8.2.2.1. MRI
      • 8.2.2.2. Ultrasound
  • 8.3. Dialysis Services
  • 8.4. Home Healthcare Services
  • 8.5. Laboratory Services
  • 8.6. Telemedicine Services

9. Third-party Medical Institutions Market, by Delivery Channel

  • 9.1. Home Care
  • 9.2. Inpatient
  • 9.3. Outpatient

10. Third-party Medical Institutions Market, by Ownership Model

  • 10.1. Private For Profit
  • 10.2. Private Non Profit
  • 10.3. Public

11. Third-party Medical Institutions Market, by Payment Model

  • 11.1. Bundled Payments
  • 11.2. Capitation
  • 11.3. Fee For Service

12. Third-party Medical Institutions Market, by End User Type

  • 12.1. Clinics
  • 12.2. Hospitals
  • 12.3. Patients

13. Third-party Medical Institutions Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Third-party Medical Institutions Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Third-party Medical Institutions Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Third-party Medical Institutions Market

17. China Third-party Medical Institutions Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. ACM Global Laboratories
  • 18.6. ARUP Laboratories, Inc.
  • 18.7. BioReference Laboratories, Inc.
  • 18.8. Cerba Research S.A.S.
  • 18.9. Charles River Laboratories International, Inc.
  • 18.10. Eurofins Scientific SE
  • 18.11. ICON Public Limited Company
  • 18.12. Laboratory Corporation of America Holdings
  • 18.13. Myriad Genetics, Inc.
  • 18.14. NeoGenomics Laboratories, Inc.
  • 18.15. PPD, Inc.
  • 18.16. Quest Diagnostics Incorporated
  • 18.17. Sonic Healthcare Limited
  • 18.18. Synlab International GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY AMBULATORY SURGERY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY AMBULATORY SURGERY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY AMBULATORY SURGERY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY X RAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY X RAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY X RAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY MRI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY MRI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY MRI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIALYSIS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIALYSIS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIALYSIS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME HEALTHCARE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY LABORATORY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY LABORATORY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY LABORATORY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY TELEMEDICINE SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY TELEMEDICINE SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY TELEMEDICINE SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE FOR PROFIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE FOR PROFIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE FOR PROFIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE NON PROFIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE NON PROFIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PRIVATE NON PROFIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY BUNDLED PAYMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY BUNDLED PAYMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY BUNDLED PAYMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CAPITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CAPITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CAPITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY FEE FOR SERVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY FEE FOR SERVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY FEE FOR SERVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 171. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 172. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 173. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 174. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 175. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 176. GCC THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 198. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 199. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 200. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 202. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 203. G7 THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 207. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 208. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 209. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 211. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 212. NATO THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 224. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DIAGNOSTIC IMAGING SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY NON IONIZING IMAGING, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY DELIVERY CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY OWNERSHIP MODEL, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY PAYMENT MODEL, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA THIRD-PARTY MEDICAL INSTITUTIONS MARKET SIZE, BY END USER TYPE, 2018-2032 (USD MILLION)